Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter.

Bhatia S, O'Bryan SM, Rivera AA, Curiel DT, Mathis JM.

Oncolytic Virother. 2016 Nov 11;5:99-113. eCollection 2016.

2.

A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.

Cabrera-Mora M, Fonseca JA, Singh B, Zhao C, Makarova N, Dmitriev I, Curiel DT, Blackwell J, Moreno A.

J Immunol. 2016 Oct 1;197(7):2748-61. doi: 10.4049/jimmunol.1501926. Epub 2016 Aug 29.

3.

A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.

Fonseca JA, Cabrera-Mora M, Kashentseva EA, Villegas JP, Fernandez A, Van Pelt A, Dmitriev IP, Curiel DT, Moreno A.

PLoS One. 2016 Apr 29;11(4):e0154819. doi: 10.1371/journal.pone.0154819. eCollection 2016.

4.

Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.

Wilkinson-Ryan I, Kim J, Kim S, Ak F, Dodson L, Colonna M, Powell M, Mutch D, Spitzer D, Hansen T, Goedegebuure SP, Curiel D, Hawkins W.

PLoS One. 2015 May 1;10(5):e0125851. doi: 10.1371/journal.pone.0125851. eCollection 2015.

5.

Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes.

Fan X, Hashem AM, Chen Z, Li C, Doyle T, Zhang Y, Yi Y, Farnsworth A, Xu K, Li Z, He R, Li X, Wang J.

Mucosal Immunol. 2015 Jan;8(1):211-20. doi: 10.1038/mi.2014.59. Epub 2014 Jul 23.

6.

Adenoviral targeting using genetically incorporated camelid single variable domains.

Kaliberov SA, Kaliberova LN, Buggio M, Tremblay JM, Shoemaker CB, Curiel DT.

Lab Invest. 2014 Aug;94(8):893-905. doi: 10.1038/labinvest.2014.82. Epub 2014 Jun 16.

7.

Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer.

Reetz J, Herchenröder O, Pützer BM.

Viruses. 2014 Apr 2;6(4):1540-63. doi: 10.3390/v6041540. Review.

8.

Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.

Dreier B, Honegger A, Hess C, Nagy-Davidescu G, Mittl PR, Grütter MG, Belousova N, Mikheeva G, Krasnykh V, Plückthun A.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):E869-77. doi: 10.1073/pnas.1213653110. Epub 2013 Feb 19.

9.

Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.

Williams BJ, Bhatia S, Adams LK, Boling S, Carroll JL, Li XL, Rogers DL, Korokhov N, Kovesdi I, Pereboev AV, Curiel DT, Mathis JM.

PLoS One. 2012;7(10):e46981. doi: 10.1371/journal.pone.0046981. Epub 2012 Oct 8.

10.

Dendritic cell-based immunity and vaccination against hepatitis C virus infection.

Zhou Y, Zhang Y, Yao Z, Moorman JP, Jia Z.

Immunology. 2012 Aug;136(4):385-96. doi: 10.1111/j.1365-2567.2012.03590.x. Review.

11.

CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.

Hangalapura BN, Timares L, Oosterhoff D, Scheper RJ, Curiel DT, de Gruijl TD.

J Gene Med. 2012 Jun;14(6):416-27. doi: 10.1002/jgm.1648. Review.

12.

Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting.

Dreier B, Mikheeva G, Belousova N, Parizek P, Boczek E, Jelesarov I, Forrer P, Plückthun A, Krasnykh V.

J Mol Biol. 2011 Jan 14;405(2):410-26. doi: 10.1016/j.jmb.2010.10.040. Epub 2010 Nov 5.

13.

A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.

Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, Korokhov N, O'Neill AM, de Gruijl TD, Glasgow JN, Tani K, Curiel DT.

Vaccine. 2009 Nov 23;27(50):7116-24. doi: 10.1016/j.vaccine.2009.09.055. Epub 2009 Sep 26.

14.

Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Thacker EE, Timares L, Matthews QL.

Expert Rev Vaccines. 2009 Jun;8(6):761-77. doi: 10.1586/erv.09.29. Review.

15.

Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes.

Zhao C, Crews CJ, Derdeyn CA, Blackwell JL.

J Virol Methods. 2009 Sep;160(1-2):101-10. doi: 10.1016/j.jviromet.2009.04.028. Epub 2009 May 3.

16.

Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.

Li HJ, Everts M, Yamamoto M, Curiel DT, Herschman HR.

Cancer Res. 2009 Jan 15;69(2):554-64. doi: 10.1158/0008-5472.CAN-08-3209.

17.

A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration.

van de Ven R, Scheffer GL, Reurs AW, Lindenberg JJ, Oerlemans R, Jansen G, Gillet JP, Glasgow JN, Pereboev A, Curiel DT, Scheper RJ, de Gruijl TD.

Blood. 2008 Sep 15;112(6):2353-9. doi: 10.1182/blood-2008-03-147850. Epub 2008 Jul 14.

18.

Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Maguire CA, Sapinoro R, Girgis N, Rodriguez-Colon SM, Ramirez SH, Williams J, Dewhurst S.

Vaccine. 2006 Jan 30;24(5):671-82. Epub 2005 Aug 24.

Supplemental Content

Support Center